Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram ; volume:24 ; number:1 ; day:11 ; month:11 ; year:2024 ; pages:1-12 ; date:12.2024
Cancer imaging ; 24, Heft 1 (11.11.2024), 1-12, 12.2024
- Creator
-
Wang, Yichen
Zhang, Xinxin
Wang, Sicong
Shi, Hongzhe
Zhao, Xinming
Chen, Yan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40644-024-00792-7
- URN
-
urn:nbn:de:101:1-2501282140206.643392661122
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Yichen
- Zhang, Xinxin
- Wang, Sicong
- Shi, Hongzhe
- Zhao, Xinming
- Chen, Yan
- SpringerLink (Online service)
Other Objects (12)
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
TKi | TKi
Is imatinib still the best choice as first-line oral TKI
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
TKI
TKI
TKi
TKi
"TKi"
TKi
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
TKi | TKi
Is imatinib still the best choice as first-line oral TKI
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
TKI
TKI
TKi
TKi
"TKi"
TKi
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
TKi | TKi
Is imatinib still the best choice as first-line oral TKI
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
TKI
TKI
TKi
TKi
"TKi"